Product
Naptumomab Estafenatox
1 clinical trial
1 indication
Indication
Bladder CancerClinical trial
A Phase 1 Trial of Naptumomab Estafenatox (NAP) in Combination With Pembrolizumab (Pembro) Preceded by Obinutuzumab (Obi) in Patients With Urothelial CancersStatus: Withdrawn, Estimated PCD: 2025-12-01